FDA Approves New Agent for Diagnosis of Advanced/Recurrent Forms of Prostate Cancer

June 4, 2021 By Dan Zeller

"In a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer.

This agent is actually approved for use in two types of patient: men suspected of having either metastatic or recurrent forms of prostate cancer — even if there is no sign of metastasis on a bone or normal CT scan."

FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer

This post originally appeared on Dan’s Journey through Prostate Cancer on May 31, 2021. It is republished with permission.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.cancerhealth.com/blog/fda-approves-new-agent-diagnosis-advancedrecurrent-forms-prostate-cancer